Seasonal Affective Disorder: Exploratory Investigation of Seasonal Variations in Brain Structure and Connectivity as a Predictor for Depressive Severity
Bright Light Therapy
Mental Disorders+2
+ Depressive Disorder, Major
+ Depressive Disorder
Diagnostic Study
Summary
Study start date: November 1, 2017
Actual date on which the first participant was enrolled.Seasonal Affective Disorder (SAD) is a subtype of Major Depressive Disorder, characterized by a recurrent temporal relationship between the season of year, the onset and the remission of a major depressive episode. Estimates of the annual prevalence state that 1-6% of the population will develop SAD with the larger prevalences found at greater extremes in latitude. SAD is most likely triggered by the shortening photoperiod experienced in the winter months leading to a deterioration of mood. Recent cross-sectional neuroimaging studies have found cellular and neurotransmitter changes in response to seasonality, ultimately having an impact on the affect of patients. Conversly, this study aims to investigate the changes in neurocircuitry related to depression and euthymic states. Patients with SAD offer a unique ability to study these changes since they have predictable triggers for the onset of depression (i.e. the winter months) and remission (i.e. the summer months).
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.23 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria for SAD Cohort 1. Male or female between the ages of 18 to 65 years, inclusive 2. Patients who are able and willing to give consent and able to attend study visits 3. Agreement to use light therapy for four weeks 4. DSM-V diagnosis of seasonal affective disorder, at least 2 year history of the illness with a Structured Interview Guide for the Hamilton Depression Rating Scale-SAD version (SIGH-SAD) score ≥ 25 at screening Exclusion Criteria for SAD Cohort 1. Current alcohol and/or substance use disorder 2. Use of cigarettes 3. Past or present psychiatric disorders (axis I and II) other than SAD 4. Taken medications approved and/or employed off-label for depression 5. Previous use of light therapy 6. Use of photosensitive medications 7. Montreal Cognitive Assessment score \< 24 8. Patients with standard contraindications for MR imaging. For example, non-MRI compatible metallic implants including cardiac pacemaker, size limitations etc. 9. Known intolerance or allergies to MRI contrast agent (Gadolinium or Magnevist) including advanced kidney disease 10. Severely impaired renal function (estimated glomerular filtration rate \<30ml/min/1.73m2) 11. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment 12. Pregnant and/or breastfeeding 13. Travelled to another a more southern latitude within 6 months of scan 14. Night shift workers 15. Are participating or have participated in clinical trial or research study in the last 30 days 16. Unable to communicate with investigator and/or staff 17. Diagnosis of a reading disability, dyslexia or significant learning disorder Inclusion Criteria for Unipolar Depression Cohort contraindications 1. Male or female between the ages of 18 to 65 years, inclusive 2. Patients who are able and willing to give consent and able to attend study visits 3. DSM-V diagnosis of major depressive disorder, with a Hamilton Depression Rating Scale score ≥ 22 at screening Exclusion Criteria for Unipolar Depression Cohort 1. Current alcohol and/or substance use disorder 2. Past or present psychiatric disorders (axis I and II) other than SAD 3. Montreal Cognitive Assessment score \< 24 4. Patients with standard contraindications for MR imaging. For example, non-MRI compatible metallic implants including cardiac pacemaker, size limitations etc. 5. Known intolerance or allergies to MRI contrast agent (Gadolinium or Magnevist) including advanced kidney disease 6. Severely impaired renal function (estimated glomerular filtration rate \<30ml/min/1.73m2) 7. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment 8. Pregnant and/or breastfeeding 9. Are participating or have participated in clinical trial or research study in the last 30 days 10. Unable to communicate with investigator and/or staff 11. Diagnosis of a reading disability, dyslexia or significant learning disorder Inclusion Criteria for Healthy Controls 1. Male or female between the ages of 18 to 65 years, inclusive 2. Patients who are able and willing to give consent and able to attend study visits 3. No current or past history of mental disorder 4. No unstable medical disorders Exclusion Criteria for Healthy Controls 1. Use of any medication for a general medical disorder and/or condition that, in the opinion of the investigator, may affect neural structure 2. Alcohol or drug-use within 24 hours of MRI 3. Pregnant and/or breastfeeding 4. Montreal Cognitive Assessment score \< 24 5. Patients with standard contraindications for MR imaging. For example, non-MRI compatible metallic implants including cardiac pacemaker, size limitations etc. 6. Known intolerance or allergies to MRI contrast agent (Gadolinium or Magnevist) 7. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment 8. Are participating or have participated in clinical trial or research study in the last 30 days 9. Unable to communicate with investigator and/or staff
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location